Development and validation of a ferroptosis-related prognostic model in pancreatic cancer [0.03%]
胰腺癌铁死亡相关预后模型的开发和验证
Chen-Jie Qiu,Xue-Bing Wang,Zi-Ruo Zheng et al.
Chen-Jie Qiu et al.
Background: The purpose of this study was to identify ferroptosis-related genes (FRGs) associated with the prognosis of pancreatic cancer and to construct a prognostic model based on FRGs. ...
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors [0.03%]
口服MDM2抑制剂idasanutlin每日和每周给药方案I期研究
Antoine Italiano,Wilson H Miller Jr,Jean-Yves Blay et al.
Antoine Italiano et al.
Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models. Methods We conducted a Phase I study of idasanutlin (microprecipitate ...
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors [0.03%]
帕唑帕尼联合替维汀治疗难治性晚期实体瘤的组合疗法可调节VEGF和c-MET水平
Shivaani Kummar,Apurva K Srivastava,Tony Navas et al.
Shivaani Kummar et al.
The vascular endothelial growth factor (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-MET signaling pathways act synergistically to promote angiogenesis. Studies indicate VEGF inhibition leads to increased levels of phosphorylated c-MET,...
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study [0.03%]
一种名为talazoparib的PARP抑制剂在日本晚期实体瘤患者中的安全性、药代动力学和初步疗效：一项Ⅰ期研究
Yoichi Naito,Yasutoshi Kuboki,Masafumi Ikeda et al.
Yoichi Naito et al.
Background: Talazoparib is a poly(ADP-ribose) polymerase enzyme inhibitor. This open-label, non-randomized, phase 1 study of talazoparib investigated the safety, pharmacokinetics, and preliminary antitumor activity in Jap...
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study [0.03%]
阿帕替尼联合多柔比星和异环磷酰胺新辅助治疗高危软组织肉瘤的疗效：一项回顾性队列研究
Zhichao Tian,Jiaqiang Wang,Jinpo Yang et al.
Zhichao Tian et al.
Background: There is a need to establish an effective neoadjuvant therapy for soft tissue sarcomas (STSs). We previously showed that apatinib, administered in combination with doxorubicin-based chemotherapy, improves the ...
Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study [0.03%]
TAS-115(一种新型的口服多激酶抑制剂)治疗骨肉瘤的疗效和安全性：一项I期扩展队列研究
Akira Kawai,Norifumi Naka,Akihiko Shimomura et al.
Akira Kawai et al.
Background osteosarcoma is a rare, primary malignant bone tumour with limited available treatments for advanced or recurrent disease, resulting in a poor prognosis for patients. TAS-115 is a novel tyrosine kinase inhibitor under investigati...
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer [0.03%]
FCN-437c（CDK4/6抑制剂）在中国HR+/HER2-晚期乳腺癌患者中的Ia期临床研究
Jian Zhang,Xiaojia Wang,Xian Wang et al.
Jian Zhang et al.
Purpose This phase 1a, first-in-human study assessed the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and antitumor activity of FCN-437c, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Methods The study enrolled femal...
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial [0.03%]
吉西他滨、卡铂和veliparib治疗多发复发/难治性生殖细胞肿瘤：GCT-SK-004二期临床试验
M Mego,D Svetlovska,M Reckova et al.
M Mego et al.
Background Patients with multiple relapsed/refractory germ cell tumours (GCTs) have an extremely poor prognosis. PARP (poly-ADP-ribose polymerase) is overexpressed in GCTs compared to normal testes, and PARP overexpression is an early event...
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis [0.03%]
自身免疫相关胆管炎和肝炎的临床特征比较分析
Masaki Takinami,Akira Ono,Takanori Kawabata et al.
Masaki Takinami et al.
Background Immune-related hepatotoxicity is often regarded as immune-related hepatitis (irHepatitis) despite including immune-related sclerosing cholangitis (irSC). This study examined the clinical differences between irSC and irHepatitis. ...
Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer [0.03%]
依维莫司治疗转移性乳腺癌的药代动力学和药效学研究
Masahide Fukudo,Kei Ishibashi,Masahiro Kitada
Masahide Fukudo
Purpose This study investigated the relationship between the pharmacokinetics and pharmacodynamics of everolimus in patients with metastatic breast cancer (mBC) in real-world practice.Methods Twenty-two patients with mBC treated with everol...